Abstract

Background

MCL is incurable. Bortezomib has shown single agent activity of 33% in relapsed MCL. Pre-clinical published data shows additive/synergistic activity of BCR.

Materials and methods

  MCL pts  ages 18 through 85, with adequate organ function unless due to lymphoma, and without HIV-1 infection or any significant medical/mental condition, were treated under an IRB-approved study, consisting of Bortezomib  1.3 mg/m2 IV given on days 1, 4, 8, and 11 (dose on day 11 omitted early on study); fractionated cyclophosphamide 300 mg/m2 q 12 hrs days 1, 2, and 3, and rituximab 375 mg/m2 day 1. Cycles were repeated every 21 days for a total of 6 or less if a response was achieved and patient qualified for SCT.

Results

From  9/2009 to 8/2012, twenty-one patients were entered in the study. Their clinical characteristics are as follows:

VARIABLERESULT
Age range (median) n = 21  55-73 (66)  
Male n = 21  14 (67%)  
MIPI :  
Low 12 (57%) 
Intermediate 6 (29%) 
High 3 (14%) 
Ki-67 range (median)  10-70 (45)  
Blastoid   7 (33%)  
AA stage IV  100%  
Nodal disease  100%  
VARIABLERESULT
Age range (median) n = 21  55-73 (66)  
Male n = 21  14 (67%)  
MIPI :  
Low 12 (57%) 
Intermediate 6 (29%) 
High 3 (14%) 
Ki-67 range (median)  10-70 (45)  
Blastoid   7 (33%)  
AA stage IV  100%  
Nodal disease  100%  

Overall response (OR)/CR rates:  71%/53%.

One patient had stable disease and 4 patients progressed. With a Median follow-up of 31 months, the median TTP was 15.8 months and the median OS was 36.4 months.

Toxicity was mainly hematologic. With 77 cycles given, grade 3 anemia was 5%, grade 3 / 4 neutropenia was 16%/9%, and grade 3 / 4 thrombocytopenia was 19%/8%. Early in the study, day 11 dose of bortezomib was omitted because of low counts by day 11 of cycle. Non-hematologic toxicity included grade 3 neutropenic fever (1%), and grade 3 fatigue (3%). No patient developed sensory neuropathy grade ¾.

Conclusion

Bortezomib can be safely combined with cyclophosphamide and rituximab and results in high rates of overall/complete responses in patients with relapsed/refractory MCL.

Disclosures:

Off Label Use: Gemcitabine, fludarabine and melphalan for transplant conditioning. Younes:Seattle Genetics, Inc.: Advisory/Scientific Board Membership Other, Honoraria, Research Funding. Pro:Seattle Genetics, Inc.: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Travel expenses Other.

Author notes

*

Asterisk with author names denotes non-ASH members.